دورية أكاديمية
أعرض في EDS

Chronic Hepatitis B Relapse Rates after Cessation of Tenofovir Alafenamide and Entecavir Therapy.

التفاصيل البيبلوغرافية
العنوان: Chronic Hepatitis B Relapse Rates after Cessation of Tenofovir Alafenamide and Entecavir Therapy.
المؤلفون: Huang CW; Division of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, Changhua 500, Taiwan., Yang CT; Division of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, Changhua 500, Taiwan., Su PY; Division of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, Changhua 500, Taiwan.; College of Medicine, National Chung Hsing University, Taichung 400, Taiwan., Chen YY; Division of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, Changhua 500, Taiwan.; College of Medicine, National Chung Hsing University, Taichung 400, Taiwan., Huang SP; Division of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, Changhua 500, Taiwan., Yen HH; Division of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, Changhua 500, Taiwan.; College of Medicine, National Chung Hsing University, Taichung 400, Taiwan.
المصدر: Biomedicines [Biomedicines] 2023 Mar 01; Vol. 11 (3). Date of Electronic Publication: 2023 Mar 01.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101691304 Publication Model: Electronic Cited Medium: Print ISSN: 2227-9059 (Print) Linking ISSN: 22279059 NLM ISO Abbreviation: Biomedicines Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG, [2013]-
مستخلص: Chronic hepatitis B (CHB) relapse occurs after the cessation of nucleos(t)ide analogues (NUC) therapy due to the waning of viral suppression. Few studies have investigated the viral relapse rate and clinical relapse rate after tenofovir alafenamide (TAF) therapy. We compared the CHB relapse rate between TAF and entecavir therapy. We enrolled patients with chronic hepatitis B who underwent TAF or entecavir therapy. NUC therapy was terminated after HBeAg loss for 1 year in HBeAg-positive patients and after undetectable serum HBV DNA on three separate tests each >6 months apart in HBeAg-negative patients. After cessation of NUC therapy, we followed alanine aminotransferase (ALT) levels at 12, 24, and 48 weeks. Serum HBV DNA levels were checked if patients showed a two-fold elevation from the upper limit of normal ALT levels (41 IU/mL). Clinical relapse (CR) was defined as a two-fold elevation in ALT levels and HBV DNA levels > 2000 IU/mL. We then investigated the CR rate of HBV after cessation of TAF and entecavir therapy at 12, 24, and 48 weeks. Of the 117 patients enrolled, 78 were in the entecavir group and 39 were in the TAF group. At 12 weeks after cessation of NUC therapy, no patients had HBV CR in the entecavir group. However, three patients (CR cumulative rate 7.9%) had CR in the TAF group. At 24 weeks, the CR cumulative rate in the entecavir and TAF groups were 1.3% and 13.2%, respectively ( p < 0.05). At 48 weeks, the CR cumulative rates were 9.2% and 24.2%, respectively ( p = 0.055). Patients in the TAF group had a higher cumulative rate of CR than those in the entecavir group (log-rank p = 0.023). Furthermore, patients in the TAF group had earlier CR times than those in the entecavir group, especially in the first 24 weeks after cessation of therapies ( p < 0.05). The cessation of TAF therapy had significantly earlier and higher CR rates than that of entecavir therapy. Close monitoring of liver function and HBV DNA levels may be necessary, especially within 24 weeks after cessation of TAF therapy.
References: Ther Clin Risk Manag. 2010 Feb 02;6:41-7. (PMID: 20169035)
J Infect Dis. 2019 Apr 19;219(10):1624-1633. (PMID: 30689910)
J Hepatol. 2015 Mar;62(3):533-40. (PMID: 25450717)
Aliment Pharmacol Ther. 2019 Jan;49(2):218-228. (PMID: 30484881)
Hepatology. 2016 Jan;63(1):284-306. (PMID: 26566246)
Hepatology. 2018 Apr;67(4):1560-1599. (PMID: 29405329)
J Infect Dis. 2018 Mar 28;217(8):1193-1201. (PMID: 29300980)
J Hepatol. 2017 Aug;67(2):370-398. (PMID: 28427875)
J Hepatol. 2017 Nov;67(5):918-924. (PMID: 28736139)
Hepatol Int. 2016 Jan;10(1):1-98. (PMID: 26563120)
Hepatology. 2013 Dec;58(6):1888-96. (PMID: 23744454)
Viruses. 2022 Feb 21;14(2):. (PMID: 35216027)
Clin Gastroenterol Hepatol. 2016 Dec;14(12):1813-1820.e1. (PMID: 27404969)
J Hepatol. 2018 Apr;68(4):672-681. (PMID: 29756595)
Clin Gastroenterol Hepatol. 2015 Nov;13(11):1984-92.e1. (PMID: 26073492)
Gastroenterology. 2012 Sep;143(3):629-636.e1. (PMID: 22659218)
JHEP Rep. 2022 Oct 28;5(1):100617. (PMID: 36466989)
Aliment Pharmacol Ther. 2016 Jul;44(1):16-34. (PMID: 27198929)
معلومات مُعتمدة: 111-CCHIRP-011 Changhua Christian Hospital
فهرسة مساهمة: Keywords: chronic hepatitis B; clinical relapse; entecavir; finite therapy; tenofovir alafenamide
تواريخ الأحداث: Date Created: 20230329 Latest Revision: 20230331
رمز التحديث: 20230331
مُعرف محوري في PubMed: PMC10045269
DOI: 10.3390/biomedicines11030752
PMID: 36979731
قاعدة البيانات: MEDLINE
الوصف
تدمد:2227-9059
DOI:10.3390/biomedicines11030752